The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics BPC 157 Dosing (Common Protocols) Oral Subcutaneous 500 mcg daily Duration: 6 weeks Intramuscular Peritendinous 1 mg daily Duration: 6 weeks Note: Not approved BPC 157 Peptide: Benefits, Dosage & Side Effects 2026 BPC 157 in Australia: Benefits, side effects, risks and legality BPC 157 Dosing (Common Protocols), Oral Subcutaneous, 500 mcg daily, Duration: 6 weeks, Intramuscular Peritendinous, 1 mg daily, Duration: 6 weeks, Note:, Not approved by FDA or